General Announcement::ASX:NASDAQ:TLX: FDA Alignment to Advance ProstACT Global Phase 3 Trial

Issuer & Securities

Issuer/ Manager
TELIX PHARMACEUTICALS LIMITED
Securities
TELIXPHAR A$650M2.375%N290730 - XS2862961492 - JWQB
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
02-Jul-2026 08:16:02
Status
New
Announcement Sub Title
ASX:NASDAQ:TLX: FDA Alignment to Advance ProstACT Global Phase 3 Trial
Announcement Reference
SG260702OTHR5K2A
Submitted By (Co./ Ind. Name)
Joanne Redfearn
Designation
Company Secretary Administrator
Effective Date and Time of the event
02/07/2026 17:00:00
Description (Please provide a detailed description of the event in the box below)
ASX:NASDAQ:TLX: FDA Alignment to Advance ProstACT Global Phase 3 Trial

Attachments

FDA Alignment to Advance ProstACT Global Phase 3 Trial.pdf
Total size =176K